Detalle Publicación

ART%EF%BF%BD%EF%BF%BDCULO

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

Autores: Nooka, A. K. ; Weisel, K.; van de Donk, N. W. C. J. ; Routledge, D.; Rodríguez Otero, Paula; Song, K.; Quach, H.; Callander, N.; Minnema, M. C.; Trudel, S.; Jackson, N. A.; Ahlers, C. M.; Im, E.; Cheng, S.; Smith, L.; Hareth, N.; Ferron-Brady, G.; Brouch, M.; Montes de Oca, R.; Paul, S.; Holkova, B.; Gupta, I.; Kremer, B. E.; Richardson, P. (Autor de correspondencia)
Título de la revista: FUTURE ONCOLOGY
ISSN: 1479-6694
Volumen: 17
Número: 16
Páginas: 1987 - 2003
Fecha de publicación: 2021
Resumen:
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ¿4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).
DOI: https://doi.org/10.2217/fon-2020-1269
Impacto:
21 citas en
Google Scholar